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ARTICLE OPEN ACCESS CLASS OF EVIDENCE
Efficacy and safety of eptinezumab in patients
with chronic migraine
PROMISE-2
Richard B. Lipton, MD, Peter J. Goadsby, MD, PhD, Jeff Smith, MD, FRCP, Barbara A. Schaeffler, MBA,








To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin gene-related
peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).
Methods
The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy–2 (PROMISE-2)
study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group
study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptine-
zumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was
change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.
Results
Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across
groups. Treatment with eptinezumab 100 and 300mgwas associated with significant reductions in
MMDs across weeks 1 to 12 compared with placebo (placebo −5.6, 100 mg −7.7, p < 0.0001 vs
placebo; 300 mg −8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were
reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis
was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over
placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%).
Conclusion
In patients with CM, eptinezumab 100 and 300 mg was associated with a significant reduction
in MMDs from the day after IV administration through week 12, was well tolerated, and
demonstrated an acceptable safety profile.
Classification of evidence
This study provides Class I evidence that for patients with CM, a single dose of eptinezumab
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Migraine is a common, disabling neurologic disorder1; its
most burdensome form is chronic migraine (CM), clinically
defined by the presence of headache on ≥15 d/mo for ≥3
months, with ≥8 d/mo of headaches linked to migraine.2
Relative to episodic migraine, CM is associated with signifi-
cantly greater disability, higher rates of comorbidity, and in-
creased direct and indirect costs.3
Reducing the burden of CM is an important goal of preventive
treatment, although randomized trials in CM are a recent
phenomenon.4–7 Currently, onabotulinumtoxinA and calci-
tonin gene-related peptide (CGRP)‒targeted monoclonal
antibodies are the only agents approved for the prevention of
CM. In the United States, diagnosis and treatment rates for
CM are low, and migraine preventive treatment is frequently
discontinued prematurely.8–13
The Prevention of Migraine via Intravenous ALD403 Safety
and Efficacy (PROMISE) phase 3 studies were randomized,
double-blind, placebo-controlled trials designed to evaluate
the efficacy, safety, and pharmacokinetics of repeat IV ad-
ministration of the monoclonal antibody eptinezumab
(ALD403) for migraine prevention in patients with episodic
migraine (PROMISE-1) and CM (PROMISE-2). Eptinezu-
mab is a monoclonal antibody that binds to the CGRP
ligand.14,15 Blockade of the CGRP pathway is an established
method in the acute and preventive treatment of migraine.16
This report presents the primary results of the PROMISE-2
study.
Methods
Standard protocol approvals, registrations,
and patient consents
The study was approved by the independent ethics com-
mittee or institutional review board for each study site. All
clinical work was conducted in compliance with current
Good Clinical Practices as referenced in the International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use guide-
lines, local regulatory requirements, and the principles of the
Declaration of Helsinki. All patients enrolled in the study
provided written informed consent before their participa-
tion. All clinical sites were required to sign a study-specific
site blinding plan. This study is registered on ClinicalTrials.
gov (NCT02974153).
Study design and patients
This phase 3, double-blind, randomized, placebo-controlled,
parallel-group, efficacy and safety study was performed at 128
sites in 13 countries (United States, Spain, Ukraine, Russian
Federation, United Kingdom, Republic of Georgia, Hungary,
Italy, Slovakia, Germany, Czech Republic, Denmark, and
Belgium) during the period of November 30, 2016, to April
20, 2018.
Adults 18 to 65 years of age (inclusive) with a diagnosis of
migraine at or before 50 years of age were eligible for partici-
pation if they had a history of CM for ≥12 months before
screening, completed the headache electronic diary (eDiary) on
≥24 of the 28 days after screening visit and before randomiza-
tion (the screening period), and experienced ≥15 to ≤26
headache days and ≥8 migraine days during the 28-day
screening period.2 Patients taking prescription or over-the-
counter medication for acute or preventive treatment of mi-
graine were eligible only if the medications had been prescribed
or recommended by a health care professional; migraine pre-
ventive medication use had to be stable for ≥3 months before
screening. Hormonal therapy (e.g., contraceptive, hormone
replacement) was also permitted if it was stable and ongoing ≥3
months before screening. Patients using barbiturates or pre-
scription opioids ≤4 d/mo were eligible for participation if use
was stable for ≥2 months before screening, and this restriction
was maintained through week 24 of the study. Other medi-
cations for the treatment of acute migraine such as triptans,
nonsteroidal anti-inflammatory drugs, and simple analgesics
were not restricted. Patients with CM and medication-overuse
headache with the exception of the overuse of barbiturates or
opioids were eligible for inclusion. The study steering com-
mittee wished to include patients using opioids and barbiturates
because more than one-third of people in the United States who
have migraine use these medications as acute prescription
treatments. The study steering committee chose to limit opioid
and barbiturate use because high use often makes the patient
refractory to preventive treatments. In pursuit of a balance be-
tween generalizability and enrolling the target population,
patients using opioids or barbiturates ≥5 d/mo were excluded.
Individuals were excluded from participation if they had a con-
founding pain disorder or clinically significant pain syndromes;
uncontrolled or untreated psychiatric conditions; acute or active
temporomandibular disorders; history or diagnosis of a head-
ache or migraine disorders that did not meet the International
Classification of Headache Disorders, 3rd edition (ICHD-3)
Glossary
ADA = anti-drug antibody; AE = adverse event; ANCOVA = analysis of covariance; CGRP = calcitonin gene-related peptide;
CM = chronic migraine; eDiary = electronic diary; HIT-6 = 6-item Headache Impact Test; ICHD-3 = International
Classification of Headache Disorders, 3rd edition; MMD = monthly migraine day; NAb = ADA with neutralizing potential;
PROMISE = Prevention of Migraine via Intravenous ALD403 Safety and Efficacy; SAE = serious AE; TEAE = treatment-
emergent AE.
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beta version (2013) Section 1.3 criteria for CM; present or
previous malignancies (except history of squamous or basal cell
carcinoma with excision for cure or breast or cervical cancer≥10
years since diagnosis/treatment without evidence of re-
currence); any active, progressive, or unstable cardiovascular,
neurologic, or autoimmune disorder; newly diagnosed or un-
controlled hypertension (mild primary hypertension that was
well controlled for ≥6 months before screening was allowed);
history or evidence of substance abuse or dependence; clinically
significant abnormal ECG findings; a concurrent medical con-
dition or laboratory abnormality during the screening period or
before dosing on day 0; body mass index ≥39 kg/m2; or recent
or planned surgery requiring general anesthesia within 8 weeks
before screening or during the duration of the study. Also ex-
cluded were patients who had received any experimental, un-
registered therapy within 30 days or 5 plasma half-lives before
screening or who had used any prohibited devices, neuro-
modulation, neurostimulation, or injectable therapy within 2
months before screening or during the screening period; bot-
ulinum toxin (any type) for migraine or for any other medical/
cosmetic reasons requiring injections within 4 months before
screening or during the screening period; monoamine oxidase
inhibitors, ketamine, methylergonovine, or nimesulide within 3
months before screening or during the screening period; any
monoclonal antibody treatment within 6 months of screening;
or eptinezumab or any monoclonal antibody targeting the
CGRP pathway. Women who were pregnant, breastfeeding, or
planning to become pregnant during the study were excluded
from participation, as were patients participating in any other
clinical study or who were positive for HIV, hepatitis B surface
antigen, or hepatitis C.
Women of childbearing potential and men with partners of
childbearing potential agreed to use adequate contraception
throughout study participation and for ≥6 months after the
last dose of study drug.
Study procedures
Patients used an eDiary to document headaches and migraines
for 4 weeks after the screening visit to confirm eligibility criteria
and to establish baseline values. Eligible patients were then
randomly assigned to receive eptinezumab 100 mg, eptinezu-
mab 300 mg, or placebo in a 1:1:1 ratio. Randomization was
stratified by the number of migraine days recorded during the
screening period (≤17 vs >17 days) and preventive medication
use during the 3 months before screening (use vs no use). The
total duration of the study was 32 weeks, with 10 scheduled
visits (screening, day 0, and weeks 2, 4, 8, 12, 16, 20, 24, and
32). After the last patient completed the week 12 visit, the
analysis of the primary endpoint was performed.
Patients received up to 2 treatments of eptinezumab or pla-
cebo (administered IV on day 0 and at week 12). Assignment
was concealed. Investigational product (either eptinezumab
100 mg or placebo) was shipped frozen on dry ice as a single-
use, preservative-free solution in a tamper-proof 2-mL type I
glass vial. Each individual vial was labeled with protocol-
specific information to meet International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use and country-specific
requirements. On randomization, study sites were provided
with enough appropriate investigational product for 1 patient
to be dosed, with subsequent treatment packs shipped auto-
matically before the next scheduled treatment visit. In-
vestigational treatments were reconstituted in a total volume
of 100 mL 0.9% saline and administered over a period of 30
minutes (plus an additional 15 minutes, per protocol, if re-
quired) by the blinded investigator. Patients were monitored
for ≥2 hours after treatment. All research participants, clini-
cians, and research personnel were blinded and remained
blinded throughout the duration of the clinical trial.
Outcome measures
Patients completed a daily eDiary from the time of screening
through week 24; this included a daily evening report (com-
pleted regardless of whether the patient had a headache) and
a headache report, which was event based (i.e., per headache).
In addition to capturing headache episodes and migraine
attacks, the daily eDiary captured acute medication use (in-
cluding type). A migraine day was defined using information
from the eDiary and followed the definition of a CM outlined
in ICHD-3. Specifically, a migraine day had to meet 3 criteria:
(1): lasted ≥4 hours or lasted 30 minutes to 4 hours and
believed by the patient to be a migraine that was relieved by
acute medication; (2) had ≥2 of the following: unilateral lo-
cation, pulsating quality, moderate or severe pain intensity,
and aggravation by or causing avoidance of routine physical
activity; and (3) had ≥1 of the following: nausea and/or
vomiting or photophobia and phonophobia.
Monthly results (e.g., monthly migraine days [MMDs]) were
based on the results of the 4-week intervals. If the headache
diary was completed for ≥21 days of a 4-week interval, the
observed frequency was normalized to 28 days. If the diary was
completed for <21 days of a 4-week interval, the results were
a weighted function of the observed data for the current interval
and the results from the previous interval, with the weight
proportional to how many days the diary had been completed.
The primary efficacy endpoint was the change from baseline in
MMDs over weeks 1 to 12, assessed with eDiary data. eDiary
data also were used for evaluating several of the key secondary
efficacy endpoints: ≥75%migraine responder rate over weeks 1
to 4, ≥75% migraine responder rate over weeks 1 to 12, ≥50%
migraine responder rate over weeks 1 to 12, percentage of
patients with a migraine on the day after dosing, change from
baseline in daily migraine prevalence from baseline to week 4,
and acute migraine medication use during weeks 1 to 12.
During the scheduled visits, patients completed several
patient-reported outcome measures, including the 6-item
Headache Impact Test (HIT-6), the 36-item Short-Form
Health Survey (version 2.0), the EuroQol 5-Dimensions
5-Levels, and the Patient Global Impression of Change. The
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Most Bothersome Symptom was evaluated as a tertiary end-
point and is not reported here.
The HIT-617,18 version 1.0, an α control endpoint in this study
for the 300mg treatment group, was administered at screening,
day 0, and at week 4, 12, 16, 24, and 32 visits to measure the
impact of headaches on the ability to function normally in daily
life. Patients rated the HIT-6 items using a Likert-type scale
anchored by “never” and “always” and including the following
response scores: never = 6, rarely = 8, sometimes = 10, very
often = 11, and always = 13. Response scores were summed to
produce a total score. Scores ≥60 were indicative of severe life
impact, 56 to 59 of substantial life impact, 50 to 55 of some life
impact, and ≤49 of little to no life impact.
Safety was assessed throughout the study via adverse event
(AE) monitoring, clinical laboratory tests, vital sign measure-
ments, physical examinations, 12-lead ECGs, the Columbia-
Suicide Severity Rating Scale,19 and concomitant medication
use. AEs of special interest also were monitored and included
AEs associated with the Columbia-Suicide Severity Rating
Scale score, cardiovascular AEs, hepatic AEs, and those asso-
ciated with study drug administration, including hypersensi-
tivity and anaphylaxis AEs.
Blood samples for immunogenicity analyses were collected on
day 0 and at week 2, 4, 8, 12, 24, and 32, including monitoring
development of anti-eptinezumab antibodies and assaying for
neutralizing potential.
Statistical methods
A total of 350 patients per group provided at least 90% power
for the primary endpoint for each comparison, assuming
a treatment effect of ≥1 day and a common SD of ≤4 days.
These sample size calculations were performed with PASS
200820 and were based on a t test that approximated the analysis
of covariance (ANCOVA) used for the primary endpoint.20
All patients who received study medication were included in
the safety and efficacy populations. For the safety analyses,
patient results were summarized within the group represent-
ing the treatment they received; if they received 2 different
doses, they were summarized in the treatment arm of the
highest dose received. For the efficacy population, patients’
results were summarized within the treatment group to which
they were randomly assigned.
A serial procedure was used to account for multiplicity asso-
ciated with >1 dose level and for multiple endpoints (figure 1).
Statistical testing was conducted to maintain a study-wide
2-sided 5% α level. The procedure first evaluated the 300 mg vs
placebo comparison for the primary endpoint. If this was sig-
nificant, testing continued to the first subset of key secondary
endpoints for 300 mg. If a significant difference was detected
for all tests within this series, the procedure then moved on to
the second subset of key secondary endpoints for 300 mg. The
procedure then moved on to the 100 mg group for the primary
endpoint and subsequently the key secondary endpoint groups
for 100 mg. If these endpoints were significant, the procedure
moved to the final key secondary endpoints for 300mg.Within
each endpoint group, the Holm procedure21 was used.
The primary efficacy endpoint was the change from baseline in
MMDs (weeks 1–12) in an ANCOVA model. Key secondary
efficacy endpoints were ≥75% migraine responder rates during
weeks 1 to 4 and 1 to 12, ≥50%migraine responder rates during
weeks 1 to 12, percentage of patients with a migraine on the day
after dosing, reduction in average daily percentage of patients
with migraine from baseline to week 4, change in HIT-6 total
score from baseline to week 12 (300 mg dose only), and acute
migraine medication use from baseline to week 12 (300mg dose
only). A ≥50% or ≥75% migraine responder was defined as
a patient who achieved ≥50% reduction or ≥75% reduction in
MMDs from baseline, respectively. These reductions were
evaluated by comparing the baseline frequency of migraine days
to themigraine frequency in 4-week intervals. Results from these
4-week intervals will be combined to produce 12-week re-
sponder endpoints. The week 1 to 4, 5 to 8, and 9 to 12 changes
frombaselinemeasures were averaged, and the average value was
compared to baseline. A percent change from baseline was de-
termined, which was used to determine the responder status.
For the key secondary endpoints (migraine responder rates and
percentage of patients with a migraine on the day after dosing),
testing was based on Cochran-Mantel-Haenszel/extended
Cochran-Mantel-Haenszel tests. The tests were stratified by
the randomization stratification factor. For the HIT-6 and
Acute Migraine Medication endpoints, an ANCOVA model
similar to the one used for the primary endpoint was used for
testing. Exploratory and safety endpoints were summarized
with descriptive statistics. All analyses were conducted with
SAS software (SAS Institute, Inc, Cary, NC) version 9.2 or
higher. Appendix 2 available from Dryad (doi.org/10.5061/
dryad.ck84q23) provides additional information on the statis-
tical analysis.
Data availability
The data reported are part of an ongoing, global sponsor-led
clinical development and registration program. Deidentified
participant data are not available for legal and ethical reasons.
Results
A total of 1,121 patients were randomly assigned; 1,072 re-
ceived treatment and were included in the safety and full
analysis populations (figure 2). Reasons that patients were
randomized but not treated included withdrawal by the pa-
tient (19 patients), loss to follow-up (3 patients), and other
(e.g., randomization errors and protocol violations 27
patients). Overall, 1,049 patients (93.6%) remained in the
study until week 12, the end of the primary efficacy period. A
total of 1,000 patients (89.2%) attended the week 24 visit, and
878 patients (78.3%) attended the week 32 visit.
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Demographic and baseline clinical characteristics are sum-
marized in table 1. The mean age was 40.5 years; 65.7% of
patients were >35 years of age. The majority of patients were
female (88.2%), white (91.0%), and not Hispanic or Latino
(92.0%). Migraine history was well balanced across treat-
ment groups. The mean age at migraine diagnosis was 22.5
years, and the mean duration of migraine diagnosis was 18.1
years. A total of 479 patients (44.7%) used concomitant
prophylactic medication. A total of 431 patients (40.2%) had
a diagnosis of medication-overuse headache at baseline.
Diagnosis was made at screening by the study investigator
using ICHD-3 beta criteria for medication-overuse headache
and was confirmed by analyses of acute medication use over
the baseline period.
Nearly all patients (99.7%) reported using ≥1 concomitant
medications during the study; concomitant medication use
was well balanced across treatment groups at the drug class
level. The most frequently reported concomitant medications
were nervous system medications (93.9%), musculoskeletal
systemmedications (57.8%), alimentary tract andmetabolism
medications (33.5%), respiratory system medications
(29.2%), genitourinary system and sex hormone medications
(26.1%), and cardiovascular system medications (22.9%).
Efficacy findings
Because the largest p value within the α-controlled primary and
key secondary endpoints was 0.0001 based on the decision rule
outlined in figure 1, the results for the primary efficacy endpoint
and all key secondary endpoints for both eptinezumab dose
groups were statistically significant (table 2).
Primary efficacy endpoint
Both 100 and 300 mg of eptinezumab demonstrated statisti-
cally significant reductions inMMDs during weeks 1 to 12 (p <
0.0001; figure 3 and table 2).MMDs decreased from 16.1 to 8.5
days in the eptinezumab 100mg group, from 16.1 to 7.9 days in
the eptinezumab 300 mg group, and from 16.2 to 10.5 days in
the placebo group. Relative to placebo, eptinezumab reduced
mean (95% confidence interval) MMDs from baseline (during
the 28-day screening period) by −2.0 (−2.9 to −1.2) days for
the 100 mg dose and −2.6 (−3.4 to −1.7) days for the 300 mg
dose. A post hoc analysis of the primary efficacy endpoint in
patients with no barbiturate or opioid use at any time during
Figure 1 Decision rule for dose levels (primary and key secondary endpoints)
HIT-6 = Headache Impact Test-6; MMD = monthly migraine
day. aStatistical significance must have beenmet to proceed
to the next step with each series. bTo proceed to the next
series, all tests in the previous series must have shown
a statistically significant difference from placebo.
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the clinical trial identified a similar reduction in mean MMDs
from baseline compared to placebo (100 mg −2.3 [−3.2 to
−1.4], p < 0.0001; 300 mg −2.8 [−3.7 to −1.9], p < 0.0001).
Key secondary efficacy endpoints
The ≥75% migraine responder rates (weeks 1–4 and 1–12)
and ≥50% migraine responder rates (weeks 1–12) are sum-
marized in figure 4 and table 2. Patients in both eptinezumab
dose groups were more likely to achieve ≥75% migraine re-
sponse during weeks 1 to 4 than were patients in the placebo
group (common odds ratios [95% confidence interval] 2.4
[1.7–3.5] for eptinezumab 100 mg and 3.2 [2.2–4.6] for
eptinezumab 300 mg). They also were more likely to achieve
≥75% migraine response during weeks 1–12 (common odds
ratios [95% confidence interval] 2.0 [1.4–3.0] for eptinezu-
mab 100 mg and 2.8 [1.9–4.0] for eptinezumab 300 mg) and
≥50%migraine response during weeks 1 to 12 (common odds
ratios [95% confidence interval] 2.1 [1.6–2.8] for eptinezu-
mab 100 mg and 2.4 [1.8–3.3] for eptinezumab 300 mg).
The migraine preventive effect of eptinezumab was statistically
significant for the 100 and 300 mg doses of eptinezumab vs
placebo after the first day after dosing (figure 4). During the 28-
day screening period, the average daily percentage of patients
with a migraine was 58%. The percentage of patients with
amigraine on the day after dosing was 28.6% in the eptinezumab
100 mg group and 27.8% in the eptinezumab 300 mg group vs
42.3% in the placebo group (both p < 0.0001 vs placebo). Es-
timatedmean changes in the average daily percentage of patients
with a migraine from baseline over weeks 1, 2, 3, and 4 were
−27.1% in the eptinezumab 100 mg group (mean difference
[95% confidence interval] from placebo −8.3% [–11.48 to
−5.05], p < 0.0001]), −29.8% in the eptinezumab 300 mg group
(mean difference from placebo −11.0% [–14.2 to −7.8], p <
0.001), and −18.8% in the placebo group. Furthermore, the
average daily percentage of patients with migraine was lower in
the eptinezumab groups than in the placebo group during each
of the first 4 weeks after dosing (figure 4).
Most patients had HIT-6 total scores in the severe range at
baseline (eptinezumab 100 mg 89.6%, eptinezumab 300 mg
88.6%, and placebo 87.4%). The mean HIT-6 scores at baseline
were 65.0 (eptinezumab 100 mg), 65.1 (eptinezumab 300 mg),
and 64.8 (placebo). By week 12, the percentage of patients with
HIT-6 scores in the severe range had been reduced to 51.4% in
the eptinezumab 100 mg treatment group, 42.9% in the epti-
nezumab 300 mg treatment group, and 60.1% in the placebo
group. Patients in the eptinezumab 300mg group demonstrated
a statistically significant improvement on the HIT-6 at week 12,
with an estimated mean difference from placebo (95% confi-
dence interval) of −2.9 (−3.9 to −1.8, p < 0.0001). The esti-
mated mean difference from placebo for the 100 mg treatment
group (a prespecified endpoint) was −1.7 and was nominally
significant (p = 0.001), although this comparison was not for-
mally included within the prespecified testing algorithm.
Both eptinezumab dose groups reduced acute medication
days from baseline to week 12 (100 mg −3.3 days, 300 mg
−3.5 days). The reduction in the 100 mg group was greater
than that in the placebo group (−1.2 [–1.7 to −0.6], p <
0.0001) but was not formally tested. The reduction in the
eptinezumab 300 mg group was significantly greater than that
in the placebo group (mean difference from placebo [95%
confidence interval] −1.4 [–1.9 to −0.9], p < 0.0001).
Safety and tolerability
A total of 1,072 patients received ≥1 doses of studymedication.
The majority of patients received both doses of eptinezumab
(100mg n = 340 [95.5%], 300mg n = 338 [96.6%]) or placebo
(n = 342 [93.4%]).
Figure 2 Patient disposition
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Adverse events
Overall, 508 patients (47.4%) experienced ≥1 treatment-
emergent AEs (TEAEs). The incidence of TEAEs was gener-
ally balanced among treatment groups (table 3).
A total of 122 patients (11.4%) had ≥1 TEAEs considered
by the investigator to be related to the study drug: 93
patients (13.2%) in the eptinezumab groups and 29
patients (7.9%) in the placebo group. The most frequently
reported study drug-related TEAEs were fatigue (eptinezumab
n = 13 [1.8%], placebo n = 3 [<1%]) and nausea (eptinezumab
n = 11 [1.6%], placebo n = 1 [<1%]). The remaining study
drug-related TEAEs occurred in <1% of patients.
No deaths were reported in this study. A total of 10 patients
(<1%) experienced a serious TEAE (7 patients who received









Mean (SD) age, y 41.0 (11.7) 41.0 (10.4) 39.6 (11.3 40.5 (11.2)
Sex, n (%)
Male 49 (13.8) 36 (10.3) 41 (11.2) 126 (11.8)
Female 307 (86.2) 314 (89.7) 325 (88.8) 946 (88.2)
Ethnicity, n (%)
Hispanic or Latino 33 (9.3) 18 (5.1) 35 (9.6) 86 (8.0)
Not Hispanic or Latino 323 (90.7) 332 (94.9) 331 (90.4) 986 (92.0)
Race, n (%)
White 332 (93.3) 322 (92.0) 321 (87.7) 975 (91.0)
Black or African American 21 (5.9) 23 (6.6) 38 (10.4) 82 (7.6)
Asian 1 (<1) 1 (<1) 1 (<1) 3 (<1)
American Indian or Alaska Native 1 (<1) 1 (<1) 1 (<1) 3 (<1)
Native Hawaiian or other Pacific Islander 0 1 (<1) 0 1 (<1)
Multiple races 1 (<1) 2 (<1) 4 (1.1) 7 (<1)
Other 0 0 1 (<1) 1 (<1)
Mean (SD) weight, kg 73.3 (15.6) 72.7 (15.3) 74.8 (16.2) 73.6 (15.8)
Mean (SD) height, cm 166.2 (8.2) 166.1 (7.9) 166.3 (7.9) 166.2 (8.0)
Mean (SD) BMI, kg/m2 26.4 (5.0) 26.2 (5.0) 27.0 (5.6) 26.6 (5.2)
Mean (SD) age at migraine diagnosis, y 22.8 (10.6) 22.0 (9.3) 22.6 (10.0) 22.5 (10.0)
Mean (SD) duration of migraine
diagnosis at baseline, y
18.3 (12.2) 19.0 (11.5) 17.0 (11.6) 18.1 (11.8)
Mean (SD) duration of CM at baseline, y 11.6 (11.7) 12.4 (11.2) 11.6 (10.9) 11.8 (11.2)
Mean (SD) No. of headache daysa 20.4 (3.1) 20.4 (3.2) 20.6 (2.99) 20.5 (3.1)
Mean (SD) No. of migraine daysa 16.1 (4.6) 16.1 (4.8) 16.2 (4.6) 16.1 (4.6)
Medication-overuse headache diagnosis, n (%) 139 (39.0) 147 (42.0) 145 (39.6) 431 (40.2)
Baseline triptan use, n (%)
≥33% of days 124 (34.8) 125 (35.7) 116 (31.7) 365 (34.0)
<33% of days 231 (64.9) 225 (64.3) 250 (68.3) 706 (65.9)
Use of opioids or barbiturates at any time, n (%) 46 (12.9) 39 (11.1) 48 (13.1) 133 (12.4)
Abbreviations: BMI = body mass index; CM = chronic migraine.
a Full analysis population; mean electronic diary–reported migraine and headache characteristics during the 28-day screening period.
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Mean MMDs, weeks 1–12
Actual
Mean 8.5 7.9 10.5
Change from baseline
Mean ‒7.7 ‒8.2 ‒5.6
Difference from placebo (95% CI) ‒2.0 (−2.9 to −1.2) ‒2.6 (−3.4 to −1.7)
p Value vs placebo <0.0001 <0.0001
Mean headache days, weeks 1–12
Actual
Mean 12.2 11.7 14.1
Change from baseline
Mean ‒8.2 ‒8.8 ‒6.4
Difference from placebo (95% CI) ‒1.7 (−2.6 to −0.9) ‒2.3 (−3.2 to −1.4)
Percentage of patients with migraine, day 1
Actual
Mean 28.6 27.8 42.3
p Value vs placebo <0.0001 <0.0001
Average daily migraine prevalence,
weeks 1‒4, %
Actual
Mean 30.6 27.9 10.5
Change from baseline
Mean ‒27.1 ‒29.8 ‒18.8
Difference from placebo (95% CI) ‒8.3 (−11.5 to −5.0) ‒11.0 (−14.2 to −7.8)
p Value vs placebo <0.0001 <0.0001
75% Migraine responder rate, weeks 1–4
Patients, n (%) 110 (30.9) 129 (36.9) 57 (15.6)
Difference from placebo (95% CI) 15.3 (9.3 to 21.4) 21.3 (15.0 to 27.6)
p Value vs placebo <0.0001 <0.0001
Odds ratio vs placebo 2.4 3.2
75% Migraine responder rate, weeks 1–12
Patients, n (%) 95 (26.7) 116 (33.1) 55 (15.0)
Difference from placebo (95% CI) 11.7 (5.8 to 17.5) 18.1 (12.0 to 24.3)
p Value vs placebo 0.0001 <0.0001
Odds ratio vs placebo 2.0 2.8
50% Migraine responder rate, weeks 1–12
Patients, n (%) 205 (57.6) 215 (61.4) 144 (39.3)
Difference from placebo (95% CI) 18.2 (11.1 to 25.4) 22.1 (14.9 to 29.2)
Continued
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eptinezumab and 3 who received placebo). The most fre-
quently reported serious TEAEs were in the system organ
class of nervous system disorders (eptinezumab n = 4 [<1%],
placebo n = 1 [<1%]); injury, poisoning, and procedural
complications (eptinezumab n = 2 [<1%], placebo n = 0);
and psychiatric disorders (eptinezumab n = 2 [<1%], pla-
cebo n = 0). One serious AE (SAE) was assessed as related to
the study drug by both the investigator and the sponsor. This
was a single episode of worsening migrainous visual phe-
nomena in a patient with a medical history of migraine with
visual aura, considered part of the disease under study, which
occurred 126 days after the second dose of eptinezumab
300 mg and lasted 4 days. No patients had life-threatening
SAEs.
A total of 13 patients (1.2%) experienced a TEAE that led to
study drug withdrawal: 3 (<1%) in the eptinezumab 100 mg
group, 8 (2.3%) in the eptinezumab 300mg group, and 2 (<1%)
in the placebo group. A total of 6 patients (1.7%) who received
eptinezumab 300 mg had the study drug withdrawn due to
hypersensitivity. Three of these events occurred after the first
dose and 3 after the second dose. All were mild to moderate in
severity, were considered related to the study drug, and oc-
curred on the treatment day. Five of the 6 events resolved on the
same day as onset (1 resolved within 2 days). The occurrence of
individual symptoms or symptom constellations coded as the
preferred term of hypersensitivity was based on the sponsor’s
established framework for evaluating treatment day events. The
clinical presentation of these events was most commonly
reported as nonspecific allergy-type reactions. Hypersensitivity
symptoms (i.e., immunoglobulin E mediated) such as hives,
angioedema, and documented respiratory manifestations were
rare.
One patient who received eptinezumab 300 mg experienced
an SAE of seizure that required hospitalization and led to







p Value vs placebo <0.0001 <0.0001
Odds ratio vs placebo 2.1 2.4
Mean acute medication days, weeks 1–12
Actual
Mean 3.3 3.2 4.3
Change from baseline
Mean ‒3.3 ‒3.5 ‒1.9
Difference from placebo (95% CI) ‒1.2 (−1.7 to −0.6) ‒1.4 (−1.9 to −0.9)
p Value vs placebo <0.0001 <0.0001
HIT-6 score, week 4
Actual
Mean 58.0 56.4 60.3
Change from baseline
Mean ‒6.9 ‒8.6 ‒4.6
Difference from placebo (95% CI) ‒2.3 (−3.4 to −1.2) ‒4.0 (−5.1 to −2.8)
HIT-6 score, week 12
Actual
Mean 58.8 57.6 60.5
Change from baseline
Mean ‒6.2 ‒7.3 ‒4.5
Difference from placebo (95% CI) ‒1.7 (−2.8 to −0.7) ‒2.9 (−3.9 to −1.8)
p Value vs placebo 0.0010 <0.0001
Abbreviations: CI = confidence interval; HIT-6 = Headache Impact Test-6; MMD = monthly migraine day.
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study drug withdrawal. This SAE was assessed by the in-
vestigator as not related to the study drug and resolved on
the same day as the hospitalization. All TEAEs of special
interest occurred in <1% of the total eptinezumab and pla-
cebo groups.
Anti-drug antibodies
The incidence of anti-eptinezumab antibodies was maximal at
24 weeks (eptinezumab 100 mg 56 of 326 patients, eptine-
zumab 300 mg 56 of 329 patients) and then declined despite
continuation of dosing (week 32: eptinezumab 100 mg 37 of
325, eptinezumab 300 mg 29 of 321 patients). There was no
clear dose-response trend in the number of patients with anti-
drug antibody (ADA)‒positive results. Among ADA-positive
patients, 26 in the eptinezumab 100 mg group and 19 in the
eptinezumab 300 mg group had ADAs with neutralizing po-
tential (NAbs). The incidence of NAbs generally increased
over time from week 2 to 24 (except at week 4). Of the 112
ADA-positive patients at week 24, NAb-positive status was
reported in 24 patients (21.4%). Formation of ADAs with or
without neutralizing potential did not affect efficacy (change
in MMDs over weeks 1–12 for ADA-positive vs ADA-
negative patients: eptinezumab 100 mg −6.1 vs −8.1, eptine-
zumab 300 mg −9.3 vs −8.1, respectively). Similarly, the
results showed no evidence of an impact from the de-
velopment of ADA, including NAbs, on the safety profile of
eptinezumab.
Discussion
PROMISE-2 demonstrated that both the 100 and 300 mg
doses of eptinezumab resulted in significant reductions in the
primary endpoint, MMDs, over weeks 1 to 12 after the first IV
administration. The ≥75% and ≥50% migraine responder
rates for the eptinezumab 100 mg and 300 mg dose groups
were greater than for placebo. These findings are consistent
with previous results from the phase 2 study of CM.22
The preventive effects of eptinezumab in patients with CM
were demonstrated on the first day after administration.
During the baseline run-in phase, patients experienced a mi-
graine headache on 57.5% of days. On day 1 after adminis-
tration, 42.3% of placebo-treated patients reported having
a migraine headache compared with 28.6% of patients treated
with eptinezumab 100 mg and 27.8% of patients treated with
eptinezumab 300 mg. This >50% reduction in migraine the
day after dosing is statistically significant. The reduction in
migraine that occurred on day 1 was maintained throughout
the study. Over weeks 1 to 4, migraine occurred in 30.6% in
the eptinezumab 100 mg group, 27.9% in the eptinezumab
300 mg group, and 38.9% in the placebo group.
Speed of onset of preventive benefit is viewed by patients as
desirable, second only to effectiveness.23 Current oral pre-
ventive therapies usually require dose titration and develop
benefits over weeks to months.24 Early onset of effect with
eptinezumab may translate into meaningful benefits for
patients with CM, allowing them to get back to work, school,
household, and family obligations sooner than with previously
available options.
Treatment with either dose of eptinezumab was associated
with reductions in days of acute medication use. Reduction in
acute medication use is an important benefit because overuse
of acute medication is associated with headache exacerbation,
side effects, and cost.25 Reduction in acute medication use has
been identified as a positive factor influencing patient accep-
tance of preventive therapy.26 Eptinezumab was well tolerated
in this study. The percentages of patients with any TEAEs
were similar across the active and placebo groups; most events
were mild or moderate in severity, and no deaths were
reported. Eptinezumab was similarly well tolerated in pre-
vious clinical study reports.22,27
The immune response to eptinezumab was characterized by
positive ADA results at every time point through week 32
(peak at week 24), with no clear dose-response trend in the
number of patients with ADA. The data show a remarkably
consistent treatment response to both the 100 and 300 mg
doses of eptinezumab, with no impacts on the safety or effi-
cacy profiles of the drug.
PROMISE-2 was designed for consistency with guidelines
recently (2018) updated by the International Headache So-
ciety Clinical Trials Standing Committee.28 It should be
noted that individuals with a history or evidence of significant
cardiovascular disease or any clinically significant concurrent
medical condition were excluded from participation; thus, the
findings may not be indicative of safety and efficacy in patients
with excluded comorbid conditions.
Figure 3 Primary endpoint: Change from baseline to week
12 in mean monthly migraine days (full analysis
population)
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The overall response to placebo was high in this trial. High
placebo rates may be attributed to a number of factors, in-
cluding the novelty of treatment, route of administration,
number of active treatment arms increasing patient expect-
ations, and number of patients previously naive to preventive
therapy.29–35 The intensive amount of patient contact with
migraine care experts throughout the trial also may have
contributed to the higher-than-expected placebo response,
including professionally supervised IV administration and
frequent follow-up contact via telephone and in-person visits.
Table 3 TEAEs reported in ≥2% of patients in any treatment group (safety population)
Eptinezumab 100 mg
(n = 356), n (%)
Eptinezumab 300 mg
(n = 350), n (%)
Placebo
(n = 366), n (%)
Total study
(n = 1,072), n (%)
Any event 155 (43.5) 182 (52.0) 171 (46.7) 508 (47.4)
Nasopharyngitis 19 (5.3) 33 (9.4) 22 (6.0) 74 (6.9)
Upper respiratory tract infection 15 (4.2) 19 (5.4) 20 (5.5) 54 (5.0)
Sinusitis 7 (2.0) 9 (2.6) 15 (4.1) 31 (2.9)
Migraine 6 (1.7) 8 (2.3) 16 (4.4) 30 (2.8)
Urinary tract infection 8 (2.2) 12 (3.4) 6 (1.6) 26 (2.4)
Nausea 6 (1.7) 12 (3.4) 7 (1.9) 25 (2.3)
Fatigue 8 (2.2) 6 (1.7) 7 (1.9) 21 (2.0)
Abbreviation: TEAE = treatment-emergent adverse event.
Figure 4 Key secondary endpoints (full analysis population)
(A) ≥75% migraine responder rates, (B) ≥50% migraine responder rates, and (C) patients with migraine on day 1 and during weeks 1 to 4.
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Despite the high placebo rates, statistical significance was
achieved for eptinezumab 100 mg and 300 mg for the primary
and all secondary endpoints.
The results of this study demonstrate that IV eptinezumab
(100 and 300 mg) is associated with a clinically meaningful
migraine preventive effect over multiple efficacy measures, is
well tolerated, and has an acceptable safety profile in adult
patients with CM. The migraine preventive effect of eptine-
zumab 100 and 300 mg was observed as early as day 1 after
administration, with >50% of patients reporting a significant
decrease in migraine incidence compared to baseline levels.
Furthermore, during the first month after the initial admin-
istration, more than one-third of patients in the eptinezumab
100 and 300 mg groups experienced a ≥75% reduction in
migraine days. Similar meaningful results were reported for
clinical and patient-reported outcomes as early as month 1.
The migraine preventive effect of eptinezumab 100 and
300 mg was maintained throughout the full 12-week dosing
interval, with patients who received a single dose of eptine-
zumab experiencing significantly greater reductions from
baseline in mean migraine days during weeks 1 to 12 relative
to those receiving placebo.
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